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Abstract: Mitotane is the only approved drug for advanced adrenocortical carcinoma (ACC) and
no biomarkers are available to predict attainment of therapeutic plasma concentrations and clinical
response. Aim of the study was to evaluate the suitability of cytochrome P450(CYP)2W1 and CYP2B6
single nucleotide polymorphisms (SNPs) as biomarkers. A multicenter cohort study including 182
ACC patients (F/M = 121/61) treated with mitotane monotherapy after radical resection (group
A, n = 103) or in not completely resectable, recurrent or advanced disease (group B, n = 79) was
performed. CYP2W1*2, CYP2W1*6, CYP2B6*6 and CYP2B6 rs4803419 were genotyped in germline
DNA. Mitotane blood levels were measured regularly. Response to therapy was evaluated as time
to progression (TTP) and disease control rate (DCR). Among investigated SNPs, CYP2W1*6 and
CYP2B6*6 correlated with mitotane treatment only in group B. Patients with CYP2W1*6 (n = 21)
achieved less frequently therapeutic mitotane levels (>14 mg/L) than those with wild type (WT)
allele (76.2% vs 51.7%, p = 0.051) and experienced shorter TTP (HR = 2.10, p = 0.019) and lower DCR
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(chi-square = 6.948, p = 0.008). By contrast, 55% of patients with CYP2B6*6 vs. 28.2% WT (p = 0.016)
achieved therapeutic range. Combined, a higher rate of patients with CYP2W1*6WT+CYP2B6*6
(60.6%) achieved mitotane therapeutic range (p = 0.034). In not completely resectable, recurrent or
advanced ACC, CYP2W1*6 SNP was associated with a reduced probability to reach mitotane
therapeutic range and lower response rates, whereas CYP2B6*6 correlated with higher mitotane
levels. The association of these SNPs may predict individual response to mitotane.
Keywords: adrenocortical carcinoma; mitotane; CYP2W1; CYP2B6; SNP; biomarker; predictive marker
1. Introduction
Adrenocortical carcinoma (ACC) is a rare tumor with an estimated incidence between 0.7 and
2.0 per million per year, and characterized by a heterogeneous prognosis mainly depending on
initial tumor stage according to the European Network for the Study of Adrenal Tumors (ENSAT)
classification [1], resection status [2,3] and Ki67 proliferation index [4–6]. Surgery remains the only
curative option for localized disease, however, despite complete tumor resection (R0), the rate of
local recurrence is high [4,7] and adjuvant treatment with mitotane is frequently recommended [8,9].
Mitotane is approved for unresectable, relapsed or metastatic ACC [10]. It has been recently shown
that up to 20% of patients with advanced ACC can experience objective response after mitotane
monotherapy, with a progression-free survival (PFS) and an overall survival (OS) of 4.1 and 18.5 months,
respectively [11]. Both in adjuvant and palliative treatment, mitotane plasma levels greater than 14
mg/L have been associated with longer survival [11–13]. However, mitotane is often associated with
several adverse events, including adrenal insufficiency, gastrointestinal-, central nervous system (CNS)-
and other endocrine-related effects [8,9].
So far, only few molecular markers have been proposed for predicting the response to mitotane
treatment, including ribonucleotide reductase M1 (RRM1) [14] and the cytochrome P450 (CYP)
2W1 [15,16]. Moreover, single nucleotide polymorphism (SNP) of another member of the CYP
superfamily, CYP2B6*6, has been proposed to correlate with mitotane plasma levels [17]. However,
these molecular markers have been investigated in small cohorts of patients and have not been
validated for clinical use.
The CYP superfamily represents the most important enzyme system involved in the
biotransformation of endogenous and exogenous substances, including drugs. SNPs in genes
coding for members of the CYP superfamily are common and usually affect the enzyme catalytic
activity, thereby modifying the drug metabolism, which might result in therapeutic failure or
increased adverse reactions [18]. CYP2W1 is one of the most recently described members of the CYP
superfamily and it is involved in the metabolism of lysophospholipids, retinoids, aromatic amines
and duocarmycin analogues [19]. Interestingly, CYP2W1 is highly expressed in fetal tissues and
some tumors, including colon cancer [20], and its expression correlates with more aggressive tumor
phenotype and poor outcome [21,22]. We previously showed that ACC patients having high CYP2W1
immunostaining at tumor level present a better response to mitotane therapy in comparison to those
with low CYP2W1 staining [15]. These results were very recently confirmed in primary ACC cell
culture [16]. Currently, it is unclear whether SNPs of CYP2W1 might affect the metabolic function of
the enzyme [23]. On the other hand, CYP2B6, in addition to CYP34A, represents an important CYP
involved in the metabolism of mitotane [24]. The most clinically relevant SNP of this gene is CYP2B6*6
that results in a decreased expression and function of the encoded enzyme [25]. In a previous series
of 27 patients with ACC, those harboring the CYP2B6*6 presented higher mitotane plasma levels in
comparison to patients with wild type (WT) [17]. However, the correlation between this SNP and the
response to mitotane treatment was not investigated.
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The aim of this study was to investigate the role of CYP2W1 and CYP2B6 SNPs as potential
markers of response to mitotane treatment, providing more insights into a personalized mitotane
therapy in patients affected by ACC. We also evaluated whether these polymorphisms could have
a role in adrenal cancer susceptibility.
2. Results
2.1. Patient Characteristics and Mitotane Treatment Details
In total, 182 patients were included in the present study. Group A included 103 patients treated
with mitotane as adjuvant therapy after radical tumor resection (R0 and RX) classified at diagnosis
as ENSAT stage I-III (n = 102) or ENSAT stage IV with a single metastasis (n = 1; Figure 1). Group B
included 79 patients with either microscopically (R1, n = 11) or macroscopically (R2, n = 4) residual
(after surgery) tumor, or recurrent disease not amenable to radical resection (n = 40), or metastatic
disease since diagnosis (ENSAT stage IV, n = 24; Figure 1).
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Figure 1. Flowchart of patients with adrenocortical carcinoma included in the present study. Among the
entire cohort, 182 patients fulfilled all inclusion criteria and were included in this study. Patients treated
with mitotane monotherapy after radical resection were included in group A (n = 103). Patients with
non-completely resectable, recurrent or advanced ACC and tr ated with mitotane monotherapy were
included in group B (n = 79). Abbreviation: R0, complete resection, R1, micr scopically n t completely
resected tumor; R2, macroscopically not completely resected tumor; RX, resection status not assessed.
Clinical and histopathological characteristics t seline of the inclu ed patients (F:M = 21:61;
median age at diagnosis 49 years, range 16 to 80 years) are summarized in Table 1. Median follow-up
of the entire cohort of patients was 45.7 months (range 5–256). No differences in mean mitotane daily
dose were reported between group A and group B (3.2 ± 1.5 vs 3.3 ± 1.7 g/day, respectively, p = 0.68).
A significantly lower number of patients in group A had disease progression during mitotane treatment
compared to those in group B (53, 51.5% vs. 69, 87.3%, chi-square = 26.05, p < 0.001).
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Table 1. Baseline clinical and histopathological characteristics of the entire cohort of patients with
adrenocortical carcinoma and in group A and B.
Baseline Characteristics of the Patients
Parameter All Patients Group A Group B p Chi-Square
n 182 103 79 - -
Sex
F 121 68 (66%) 53 (67.1%) 0.88 0.023
M 61 35 (34%) 26 (32.9%)
Age yrs 49 (16–80) 47 (18–75) 51 (16–80) 0.027 -
Tumor size cm 10 (2–24) 10 (2–24) 11 (3–24) 0.05 -
Hormone secretion
0.007 16.02
Cortisol (alone or with
other steroids) 80 (44.0%) 37 (35.9%) 43 (54.4%)
Androgens 15 (8.2%) 14 (13.6%) 1 (1.3%)
Aldosterone 4 (2.2%) 4 (3.9%) 0 (0%)
Estrogens 2 (1.1%) 1 (1.0%) 1 (1.3%)
Inactive 53 (29.1%) 33 (32.0%) 20 (25.3%)
Unknown 28 (15.4%) 14 (13.6%) 14 (17.7%)
ENSAT Tumor Stage at
diagnosis
<0.001 35.45I–II 108 (59.3%) 75 (72.8%) 33 (41.8%)
III 49 (27.0%) 27 (26.2%) 22 (27.8%)
IV 25 (13.7%) 1 (1.0%) 24 (30.4%)
Resection Status
<0.001 56.60
R0 114 (62.6%) 83 (80.6%) 31 (39.2%)
RX 34 (18.7%) 20 (19.4%) 14 (17.7%)
R1/R2 28 (15.4%) 0 (0%) 28 (15.4%)
unknown 6 (3.3%) 0 (0%) 6 (7.6%)
Ki67% proliferation index a 17 (1–90) 20 (1–90) 10 (1–60) 0.076 -
Weiss score b 6 (2–9) 6 (2–9) 6 (3–9) 0.19 -
Data were reported as total number and percentage of patients or as median value and range. a Ki67%: for 12 patients
Ki67% was unknown (6 for each group). b Weiss score: only one patient had a Weiss score = 2, but it was associated
with a high proliferation index (Ki67% = 20%). Statistical analyses between group A and group B were performed
by Mann-Whitney test and Chi-square test for continuous or dichotomic variables, respectively. A p value in bold
type denotes a significant difference (p < 0.05). Legend: F, female; M, male; n, number of patients; Resection Status:
0, complete resection; 1, microscopically not completely resected tumor; 2, macroscopically not completely resected
tumor; X, not assessed; yrs, years.
Patients in group A had a significantly longer median time to progression (TTP) of 34.0 months
(95% confident interval (95% CI) 5.13–62.9) under mitotane treatment compared to those in group B,
who had a median TTP of 6.0 months (95% CI 3.3–8.7; p < 0.001). Similarly, median disease-specific
survival (DSS) was significantly longer in group A than group B (median DSS not reached vs 38 months
(95% CI 15.0–60.9), respectively; p < 0.001).
2.2. CYP2W1 and CYP2B6 Allele Frequency
The Hardy Weinberg equilibrium (HWE) was calculated within German and Italian subgroups
as these were the two major population included in the study (n = 117 and 50, respectively) [26].
HWE was not calculated for Greek, Russian, Romanian, Croatian and Serbian patients since the number
of included patients originating from these countries was too small (n = 6, 4, 3, 1 and 1, for each group).
All investigated allele variants were in HWE, except for a slightly excess of homozygotes for CYP2W1*6
in the German population (p = 0.03) that it could be due to population stratification [26], and it results
not clinically relevant [27].
Regarding CYP2W1*2, 155 patients (85.2%) had WT allele (GG genotype), 26 (14.3%) were
heterozygous (GA genotype) and only 1 (0.5%) was homozygous (AA genotype). For CYP2W1*6,
134 cases (73.6%) had WT allele (CC genotype), 40 (22.0%) were heterozygous (CT genotype) and 8
(4.4%) were homozygous (TT genotype). The allele frequencies for CYP2W1*2 and CYP2W1*6 were 8%
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and 15% respectively, and are comparable to those found in the European population (8% and 17% for
CYP2W1*2 and CYP2W1*6, respectively).
Regarding CYP2B6*6, 103 patients (56.7%) had WT allele (GG genotype), 62 (34%) were
heterozygous (GT genotype) and 17 (9.3%) were homozygous (TT genotype). For the CYP2B6
intronic variant, 86 subjects (47.3%) had WT allele (CC genotype), 84 (46.1%) were heterozygous (CT
genotype) and 12 (6.6%) were homozygous (TT genotype). The allele frequencies for CYP2B6*6 and
CYP2B6 intronic variant were 26% and 30%, respectively, and were comparable to those found in the
European population (28% for both CYP2B6*6 and CYP2B6 intronic variant).
Due to the low number of homozygous patients, we considered the patients with heterozygosity
or homozygosity for each SNPs as one single group (patients with SNP). None of the evaluated SNPs
correlated with hormone secretion status, ENSAT tumor stage at diagnosis and ki67 proliferation index.
2.3. Achievement of Mitotane Therapeutic Levels
We did not find any correlation between the evaluated SNPs and the achievement of mitotane
target levels (≥14 mg/L) in group A (patients treated with mitotane as adjuvant therapy after radical
tumor resection).
In group B,CYP2W1*6 andCYP2B6*6SNPs correlated with the achievement of mitotane therapeutic
levels. We observed that only five patients with CYP2W1*6 (23.8%) achieved mitotane therapeutic
range compared to 28 (48.5%) of those with CYP2W1*6 WT (odds ratio (OR) = 0.47, 95% CI 0.18–1.07,
chi-square = 3.794, p = 0.051; Figure 2A). Opposite to this, the majority of patients with CYP2B6*6
(n = 22, 55.0%) achieved mitotane therapeutic levels compared to 11 patients (28.2%) with CYP2B6*6
WT (OR = 1.70, 95% CI 1.10–2.36, chi-square = 5.829, p = 0.016; Figure 2B). Accordingly, when we
combined both SNPs, a significantly higher proportion of patients with CYP2W1*6 WT and CYP2B6*6
(n = 20 out 33, 60.6%) achieved mitotane target levels compared to patients with CYP2W1*6 and
CYP2B6*6 WT (n = 3 out 14, 21.4%; OR = 5.64, 95% CI 1.32–24.18, p = 0.02) and those patients with
both SNPs WT (n = 8 out 25, 32%; OR = 3.27, 95% CI 1.10–9.75, p = 0.037; Figure 2C).
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Figure 2. Correlation between the presence of CYP2W1*6 and/or CYP2B*6 SNPs with the achievement
of mitotane target levels in group B (n = 79). (A) Relationship between presence of CYP2W1*6 and
achievement of mitotane target levels. (B) Relationship between presence of CYP2B6*6 and achievement
of mitotane target levels (C) Relationship with the achievement of target itotane levels based on the
combination of the two SNPs. Statistical analysis was performed by Chi-square test on absolute values.
Then we evaluated the potential factor that could predict the achievement of the mitotane
therapeutic levels during the TTP by multivariate logistic analyses, including the two SNPs CYP2W1*6
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and CYP2B6*6 and the mean mitotane dose during treatment (Table S1). None of the evaluated
parameters could predict the achievement of the mitotane target levels in group A, whereas CYP2B6*6
was an independent factor to predict mitotane target levels in group B (OR 2.89, 95% CI 1.06–7.85,
p = 0.04; Table S1).
2.4. Response to Mitotane Treatment
2.4.1. Group A: Patients with Completely Resected Tumor
In line to what observed for the achievement of mitotane target levels, none of the evaluated
SNPs correlated with TTP in group A (Table 2). In this group, only the achievement of the mitotane
therapeutic range and Ki67 index significantly correlated with TTP at both univariate and multivariate
analysis [hazard ratio (HR) = 2.11, 95% CI 1.17–3.82, p = 0.013, and HR = 3.25, 95% CI 1.64–6.41,
p = 0.001, respectively, in the multivariate analysis; Table 2]. Both parameters significantly correlated
also with DSS (HR = 2.25, 95% CI 1.02–4.96, p = 0.046 for the achievement of mitotane target levels;
HR = 2.46, 95% CI 1.03–5.87, p = 0.043 for Ki67 index; Table 2).
Table 2. Univariate and multivariate analysis correlating clinical and histopathological parameters and the
investigated SNPs with response to mitotane treatment and disease-specific survival in group A (n = 103).
Group A
Parameters
TTP DSS
Univariate Multivariate Univariate Multivariate
p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI)
Mitotane
therapeutic
range
0.024 1.92(1.09–3.37) 0.019
2.04
(1.13–3.71) 0.032
2.38
(1.08–5.26) 0.046
2.25
(1.02–4.96)
ENSAT stage at
diagnosis 0.13
1.57
(0.88–2.79) n.a - 0.77
1.44
(0.48–2.96) n.a -
Ki67 index <0.001 3.46(1.76–6.78) 0.001
3.06
(1.55–6.05) 0.026
2.68
(1.13–6.35) 0.043
2.46
(1.03–5.87)
Hormonal
secretion 0.055
1.8
(0.99–3.30) n.a. - 0.08
2.22
(0.92–5.39) n.a. -
Age at diagnosis 0.93 1.03(0.59–1.78) n.a. - 0.51
0.79
(0.21–1.31) n.a. -
CYP2W1*2 0.15 0.54(0.23–1.26) n.a. - 0.12
0.21
(0.03–1.53) n.a. -
CYP2W1*6 0.39 1.30(0.71–2.34) n.a. - 0.79
1.12
(0.49–2.56) n.a. -
CYP2B6*6 0.77 0.92(0.52–1.61) n.a. - 0.63
1.21
(0.56–2.58) n.a. -
CYP2B6 intronic
variant 0.07
0.61
(0.35–1.05) n.a. - 0.29
0.66
(0.31–1.42) n.a. -
Group A includes patients who were treated with mitotane as adjuvant therapy after radical tumor resection.
For ENSAT tumor stage, stage I–II vs. III–IV (local advanced/metastasized) was considered. For Ki67 index, a cut-off
of 20% was considered. For hormonal secretion, cortisol alone or in combination vs other steroids or inactive tumor
was considered. Statistical analyses were performed by Cox proportional hazard regression and for the multivariate
models were considered only those parameters that were statistically significant at the univariate analysis. A p value
in bold type denotes a significant difference (p < 0.05). Abbreviations: 95% CI, 95% confidence intervals, DSS,
disease specific survival; HR, hazard ratio; n.a., not applicable; TTP, time to progression under therapy.
Moreover, we observed that the achievement of the mitotane target levels significantly influence
the TTP in patients with CYP2W1*6 or CYP2B6*6 SNPs (Table 3). Particularly, patients with one of the
two SNPs and mitotane plasma levels <14 mg/L presented a significantly increased risk of recurrence
compared to those who achieved the mitotane target levels (HR = 3.45, 95% CI 1.45–10.42, for patient s
with CYP2W1*6 and HR = 3.58, 95% CI 1.22–10.49 for those with CYP2B6*6). A significantly shorter
DSS was observed only for patients with CYP2B6*6 (HR = 7.10, 95% CI 1.97–25.60; Table 3).
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Table 3. Time to progression and disease-specific survival for patients with CYP2W1*6 or CYP2B6*6
correlating with the achievement of the mitotane target levels in group A.
Group A (n = 98) *
SNPs n
TTP DSS
Median TTP
Months HR (95% CI) p
Median DSS
Months HR (95% CI) p
CYP2W1*6
target levels 15 Not reached Not reached
mitotane levels <14 12 10.5 3.45(1.45–10.42) 0.03 60.0
2.72
(0.65–11.3) 0.17
CYP2W1*6 WT
target levels 36 66.0 Not reached
mitotane levels <14 35 22.0 1.61(0.81–0.65) 0.18 Not reached
2.40
(0.93–6.21) 0.07
CYP2B6*6
target levels 23 66.0 Not reached
mitotane levels <14 14 5.0 3.58(1.22–10.49) 0.02 60.0
7.10
(1.97–25.60) 0.003
CYP2B6*6 WT
target levels 28 53.0 Not reached
mitotane levels <14 33 19.0 1.57(0.77–3.20) 0.22 Not reached
1.30
(0.47–3.61) 0.32
Target mitotane levels was defined when the mitotane blood level was ≥14 mg/L for at least half of the treatment
period. Statistical analysis was performed by Kaplan-Meier and the differences between the groups by Log Rank
(Mantel-Cox) test. A p value in bold type denotes a significant difference (p < 0.05). Abbreviations: 95% CI, 95%
confidence intervals, DSS, disease specific survival; HR, hazard ratio; TTP, time to progression under therapy.
* 5 patients among the entire group A (n = 103) had missing data and were not included in this analysis.
2.4.2. Group B: Patients with Not Completely Resectable, Recurrent or Advanced ACC
Conforming to the correlation of CYP2W1*6 SNP with the achievement of mitotane target level in
group B, we observed that patients with CYP2W1*6 had a significantly shorter TTP (median TTP 3
months, 95% CI 0.76–5.24) compared to those with CYP2W1*6 WT (median TTP 8 months, 95% CI
5.20–10.80; HR = 2.10, 95% CI 1.13–3.92, p = 0.019; Figure 3A). This correlation remained true also after
adjusting the survival curve for sex (chi-square 4.45, p = 0.035), age (chi-square = 5.21, p = 0.02) and
ENSAT stage at diagnosis (chi-square = 4.67, p = 0.031).
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Figure 3. CYP2W1*6 SNP and response to mitotane therapy in group B (n = 79). (A) Time to progression
under therapy (TTP) in patients with CYP2W1*6 compared to those having the wild-type (WT) allele
(median TTP 3 vs. 8 months). Statistical analysis by Kaplan-Meier survival curves and Log Rank
(Mantel-Cox) test. (B) Disease control rate (DCR) according to RECIST 1.1 criteria [28]. DCR was
defined as the proportion of patients whose best response was complete response (CR) or partial
response (PR) or stable disease (SD) according to RECIST 1.1 criteria. Statistical analysis for DCR was
performed by Chi-square test on absolute values.
However, at multivariate analysis, including the achievement of the mitotane target levels and the
time to progression pre-mitotane treatment (preM-TTP), considered as the time from ACC diagnosis to
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first radiological evidence of recurrence or progression, the CYP2W1*6 SNP was not more significant
(HR = 1.54, 95% CI 0.91–2.61, p = 0.10; Table 4).
Table 4. Univariate and multivariate analysis correlating clinical and histopathological parameters
and the investigated SNPs with the response to mitotane treatment and the disease-specific survival in
group B (n = 79).
Group B
Parameters
TTP DSS
Univariate Multivariate Univariate Multivariate
p HR (95% CI) p HR (95% CI) p HR (95% CI) p HR (95% CI)
Mitotane
therapeutic range 0.003
2.11
(1.84–3.47) 0.002
2.29
(1.37–3.85) 0.77
1.69
(0.94–3.04) n.a. -
PreM-TTP 0.012 0.67(0.49–0.92) 0.004
0.64
(0.47–0.87) 0.004
1.65
(1.17–2.32) 0.13
0.68
(0.42–1.12)
Ki67 index 0.057 1.63(0.99–2.69) n.a. - <0.001
3.07
(1.67–5.65) 0.037
2.07
(1.05–4.10)
R status 0.24 1.35(0.81–2.25) n.a. - <0.001
3.34
(1.80–6.20) 0.09
1.92
(0.88–4.16)
Hormonal
secretion 0.21
0.70
(0.40–1.22) n.a. - 0.19
0.65
(0.35–1.23) n.a. -
Age at diagnosis 0.97 0.99(0.61–1.59) n.a. - 0.78
0.93
(0.53–1.61) n.a. -
CYP2W1*2 0.97 1.01(0.52–1.98) n.a. - 0.65
1.18
(0.57–2.44) n.a. -
CYP2W1*6 0.028 1.78(1.06–2.99) 0.10
1.54
(0.91–2.61) 0.36
1.32
(0.72–2.43) n.a. -
CYP2B6*6 0.54 1.01(0.52–1.98) n.a. - 0.80
1.08
(0.62–1.88) n.a. -
CYP2B6 intronic
variant 0.49
1.18
(0.73–190) n.a. - 0.88
1.04
(0.59–1.83) n.a. -
Group B includes patients with not completely resected tumor, or recurrent disease not amenable to radical resection
or metastatic disease at diagnosis who were treated with mitotane monotherapy. For the time from ACC diagnosis
to recurrence or metastasis, time to progression pre-mitotane treatment (preM-TTP) ≤3 months, between 3 and
24 months, and ≥24 month were considered. For Ki67 index, a cut-off of 20% was considered. For R status at
diagnosis, R0/RX vs. R1/R2 was considered. For hormonal secretion, cortisol alone or in combination vs other steroids
or inactive tumor was considered. Statistical analyses were performed by Cox proportional hazard regression
and for the multivariate models were considered only those parameters that were statistically significant at the
univariate analysis. A p value in bold type denotes a significant difference (p < 0.05). Abbreviations: 95% CI,
95% confidence intervals, DSS, disease specific survival; HR, hazard ratio; n.a., not applicable; preM-TTP, time to
progression pre-mitotane treatment; R, resection status; TTP, time to progression under therapy.
Evaluating the best overall response to mitotane according to RECIST criteria [28], we observed
that among patients with CYP2W1*6 SNP, only 1 patient (4.8%, 95% CI 0.1–23.8) achieved complete
response (CR) and 1 achieved partial response (PR) after treatment compared to 4 patients (6.9%,
95% CI 1.9–16.7) and 7 patients (12.1%, 95% CI 5.0–23.3), respectively, with CYP2W1*6 WT (Table 5).
Disease control rate (DCR) was 71.4% in CYP2W1*6 SNP compared to 37.9% of those with CYP2W1*6
WT (OR = 4.09, 95% CI 1.38–12.1, chi-square = 6.948, p = 0.008; Figure 3B).
On the other side, CYP2B6*6 SNP showed no association with TTP. In fact, no difference was observed
between patients with CYP2B6*6 (median TTP 8 months, 95% CI 4.92–11.08) and those with CYP2B6*6 WT
(median TTP 5 months, 95% CI 2.38–7.62; HR = 0.85, 95% CI 0.52–1.39, p = 0.52). Similar to this, CYP2B6*6
SNP did not correlate with DCR (OR = 1.31, 95% CI 0.54–3.19, chi-square = 0.36, p = 0.55).
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Table 5. Best overall response to mitotane treatment according to RECIST 1.1 criteria in group B (n = 79).
Best Response CYP2W1*6 WT (n = 58) CYP2W1*6 (n = 21)
n % (95% CI) n % (95% CI)
Complete response 4 6.9% (1.9–16.7) 1 4.8% (0.1–23.8)
Partial response 7 12.1% (5.0–23.3) 1 4.8% (0.1–23.8)
Stable disease 25 43.1% (30.2–56.8) 4 19.0% (5.4–41.9)
Progressive disease 22 37.9% (25.5–51.6) 15 71.4% (47.8–51.6)
Patients with not completely resected tumor, or recurrent disease not amenable to radical resection or metastatic
disease at diagnosis (group B) were divided according the CYP2W1*6 SNP. The objective tumor response for target
lesions was evaluated according to RECIST 1.1 criteria [28] as follow: complete response as the disappearance of all
target lesions; partial response when at least a 30% decrease in the sum of diameters of target lesions; progressive
disease when at least a 20% increase in the sum of diameter of target lesions; stable disease when neither sufficient
shrinkage to qualify for partial response nor sufficient increase to qualify for progression. Abbreviations: 95% CI,
95% confidence intervals, n, number of patients; SNP, single nucleotide polymorphism.
The combination of CYP2W1*6 and CYP2B*6 significantly correlated with TTP (chi-square =
4.27, p = 0.039; Figure S1). Particularly, patients with CYP2W1*6 and CYP2B6*6 WT (n = 14) had
a significantly shorter TTP (median TTP 3 months, 95% CI 1.79–4.21) compared to those with CYP2W1*6
WT and CYP2B6*6 WT (n = 25, median TTP 9 months (95% CI 0–18.79), HR = 3.0 (95% CI 1.51–5.94),
p = 0.035) and to those with CYP2W1*6 WT and CYP2B6*6 (n = 33, median TTP 8 months (95% CI
5.20–10.80), HR = 2.67 (95% CI 1.40–5.06), p = 0.014). No difference was found compared to patients
with CYP2W1*6 and CYP2B6*6 (n = 7, median TTP 4 months (95% CI 0–9.13), HR = 1.33 (95% CI
0.54–3.30), p = 0.38).
Interestingly, as observed for group A, the achievement of the mitotane target levels significantly
influenced the TTP of patients with CYP2W1*6 or CYP2B6*6 SNPs (Table 6). In particular, patients with
CYP2W1*6 or CYP2B6*6 SNPs who not achieved the mitotane range presented a significantly increased
risk of progression compared to those who had mitotane levels within the target range (HR = 3.52,
95% CI 1.16–10.65 and HR = 5.59, 95% CI 2.40–13.00). A significantly shorter DSS was observed only
for patients with CYP2B6*6 who did not achieve the therapeutic target mitotane levels (HR = 3.89, 95%
CI 1.61–9.43; Table 6).
Table 6. Time to progression and disease-specific survival for patients with CYP2W1*6 or CYP2B6*6
correlating with the achievement of the mitotane target levels in group B.
Group B (n = 79)
SNPs n
TTP DSS
Median TTP
Months HR (95% CI) p
Median DSS
Months HR (95% CI) p
CYP2W1*6
target levels 5 18.0 115.0
mitotane levels <14 16 3.0 3.52 (1.16–10.65) 0.03 36.0 1.67 (0.52–5.39) 0.39
CYP2W1*6 WT
target levels 28 13.0 75
mitotane levels <14 30 5.0 1.95 (1.07–3.55) 0.03 40 1.45 (0.73–2.86) 0.23
CYP2B6*6
target levels 22 15.0 75.0
mitotane levels <14 18 4.0 5.59 (2.40–13.00) <0.0001 25.0 3.89 (1.61–9.43) 0.003
CYP2B6*6 WT
target levels 11 13.0 50.5
mitotane levels <14 28 4.5 1.37 (0.34–2.91) 0.42 58.0 0.99 (0.39–2.43) 0.95
Target levels for mitotane was defined when the mitotane blood level was ≥14 mg/L for at least half of the treatment
period. Statistical analysis was performed by Kaplan-Meier and the differences between the groups by Log Rank
(Mantel-Cox) test. A p value in bold type denotes a significant difference (p < 0.05). Abbreviations: 95% CI, 95%
confidence intervals, DSS, disease specific survival; HR, hazard ratio; TTP, time to progression under therapy.
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In this group of patients with advanced disease, none of the evaluated SNPs correlated with
the DSS (Table 4). Only Ki67 index correlated with DSS at both univariate and multivariate analysis
(HR = 2.07, 95% CI 1.05–4.10, p = 0.037 at multivariate analysis; Table 4).
2.5. Adverse Events Associated to Mitotane Treatment
Mitotane-related adverse events were similar in the two groups (chi-square = 17.88, p = 0.53),
and the most frequent adverse event was an increase of GGT reported in 94.5% and 93% of patients in
group A and B, respectively. None of the evaluated SNPs correlated with the type of adverse events
(chi-square = 8.78 p = 0.98 for CYP2W1*2; chi-square = 23.55, p = 0.21 for CYP2W1*6; chi-square = 23.15,
p = 0.23 for CYP2B6*6; chi-square = 17.61, p = 0.0.55 for CYP2B6 intronic variant) or with the number
of adverse events (Eta-square coefficient was: 0.005 for CYP2W1*2; 0.006 for CYP2W1*6; 0.00009 for
CYP2B6*6; 0.0005 for CYP2B6 intronic variant).
2.6. Mitotane Metabolites and Correlation with CYP2W1*6 and CYP2B6*6 SNPs
In a subgroup of 29 patients with available plasma samples (14 in group A and 15 in group
B), we measured mitotane metabolites 1,1-(o,p′-dichlorodiphenyl)-2,2 dichloroethene (o,p′-DDE) and
1,1-(o,p′-dichlorodiphenyl) acetic acid (o,p′-DDA) together with mitotane (o,p′-DDD), and correlated
them with CYP2W1*6 and CYP2B6*6 SNPs.
In group A, we observed that patients with CYP2B6*6 (n = 5) had significant higher levels of
o,p′-DDE (median levels 3.45 µg/mL (range 1.54–4.37)) compared to patients with CYP2B6*6 WT
(n = 9; median levels 0.88 µg/mL (range 0.02–3.57), fold change 2.58 (95% CI −0.05–3.44), p = 0.04;
Supplementary Figure S2A). No correlations were found between CYP2B6*6 SNP and o,p′-DDA
or o,p′-DDD (Figure S2B,C). However, no correlations were shown between CYP2W1*6 SNP and
mitotane metabolites.
In group B, patients with CYP2W1*6 (n = 5) had significant lower levels of o,p′-DDE [median
levels 0.17 µg/mL (range 0–1.61)] compared to patients with CYP2B6*6 WT [n = 10; median levels
1.92 µg/mL (range 0.06–7.05), fold change −1.74 (95% CI −4.04 to 0.11), p = 0.039; Supplementary
Figure S2D). A trend to lower o,p′-DDA levels were also observed in patients with CYP2W1*6 (median
levels 3.50 µg/mL (range 1.20–10.39) vs 16.74 µg/mL (range 3.25–44.96), fold change −13.25 (95% CI
−25.49 to 0.50), p = 0.058; Figure S2E). No significant correlation was observed for o,p′-DDD levels and
CYP2W1*6 (Figure S2F), as well as between CYP2B6*6 SNP and mitotane metabolites.
3. Discussion
ACC is a rare tumor with heterogeneous prognosis [1,9] and the only approved drug by FDA and
EMA for the treatment of advanced disease is mitotane [10,11]. It has been demonstrated that mitotane
levels of 14 mg/L or greater are significantly associated with longer survival [11–13]. This was confirmed
also in our study, where the achievement of the mitotane target levels represented an independent
and, together with Ki67 index, the strongest predictor of tumor recurrence or progression both in
patients after radical resection and in those with not completely resected, recurrent or advanced ACC.
For that reason, the achievement of the target range should be considered as the goal of the mitotane
treatment [9]. Currently, no one of the proposed biomarkers, which were previously described to
predict response and attainment of therapeutic plasma concentrations [14–17], is used in clinical
practice since they have not been validated. In this multicenter study, we evaluated SNPs of CYP2W1
and CYP2B6 as potential predictive markers of response to mitotane in a large cohort of patients treated
with mitotane monotherapy as first pharmacological therapy either after radical resection (group A) or
in not completely resectable, recurrent or advanced ACC (group B).
First, we showed that all investigated SNPs were in Hardy-Weinberg Equilibrium in our cohort
of ACC, except for a slightly deviations toward an excess of homozygotes for the CYP2W1*6 in
German patients. This slight discrepancy is not clinically relevant [27] and could be due to population
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stratification [26], such as assortative mating. Thus, we can confirm that there is no association between
the investigated SNPs and an increased ACC risk, as already reported for colon cancer [23].
Among the investigated SNPs, only CYP2W1*6 and CYP2B6*6 SNPs revealed to be associated with
mitotane plasma levels. These results are in accordance to previous studies that reported an association
between the investigated SNPs and an increase or decrease metabolism of different drug [23,29].
Moreover, we validated the association between CYP2B6*6 and higher mitotane plasma levels in
a larger cohort of ACC patients [17]. We demonstrated that both SNPs were significantly associated
with achievement of mitotane target levels. Particularly, the majority of patients with CYP2W1*6 did
not achieved the mitotane therapeutic range, whereas most patients with CYP2B6*6 attained the target
levels, showing an opposite effect. This was evident also when we combined the two SNPs. Moreover,
we observed that patients with CYP2W1*6 had a significantly shorter TTP and a poorer response to
mitotane therapy compared to those with WT allele. However, this association was not significant in
a multivariate analysis, suggesting that CYP2W1*6 has more likely an indirect effect on the response
to mitotane treatment through influencing the achievement of mitotane target levels. In this study,
the role of CYP2W1*6 and CYP2B6*6 on mitotane treatment was evident only in patients with not
completely resectable, recurrent or advanced ACC (group B). The discrepancy observed between two
groups could be due to the presence of the tumor itself. In fact, we already demonstrated that CYP2W1
is highly expressed in ACC [15] at both RNA and protein levels, and it could be locally (at tumor level)
involved in mitotane metabolism, thus impacting the achievement of the target range. In patients after
radical resection (group A), there is no local metabolism of mitotane, explaining the lack of effect of
CYP2W1 phenotype on mitotane levels. We assumed that a similar mechanism could be the case for
the CYP2B6 phenotypes. While no one demonstrated until now that this cytochrome is overexpressed
in ACC, there is however evidence of gene amplifications associated with ACC [30].
To better investigate the potential role of the CYP2W1*6 and CYP2B6*6 SNPs on mitotane
metabolism, we measured two mitotane metabolites. We found that o,p′-DDE levels positively
correlated with CYP2B6*6 and negatively with CYP2W1*6. Although the antitumor activity of mitotane
metabolites is controversial [12,31–33], o,p′-DDE, together with o,p′-DDA, reflects the metabolism
of mitotane. Thus, an alteration of o-p’-DDE plasma levels might mirror an alteration of mitotane
metabolism. Therefore, a decrease of enzymatic activity associated with CYP2B6*6 SNPs might result
in an increase of mitotane plasma levels as already demonstrated for other drugs, such as efavirenz [34].
On the other hand, the effect of CYP2W1 SNPs is currently unclear and, contrary to what has been
described for duocarmycin analogs in colon cancer cells [23], CYP2W1*6 may have a different catalytic
capacity for mitotane metabolism.
With this study we confirmed that the achievement of the mitotane therapeutic range is the
most remarkable factor to predict the response to mitotane treatment both in adjuvant setting and in
recurrent/advanced ACC [12], as well as to predict the DSS after radical tumor resection [11,12]. We were
also able to confirm the relevant role of clinical and histopathological parameters, including ENSAT
tumor stage, preM-TTP, Ki67 index, R status, and the hormonal status as significant prognostic markers
of survival [1,2,4–6,35].
Due the rarity of ACC, it appears difficult to perform prospective studies including
a large number of patients homogeneously treated, and till now only retrospective studies were
performed [8,11,13–15,17,36]. The only prospective study evaluating the efficacy of mitotane in
adjuvant treated patients has just stop recruitment (ClinicalTrials.gov Identifier: NCT00777244). In our
study, thanks to its multicenter design, we were able to include a very large number of patients treated
with mitotane monotherapy as first-line medical treatment (n = 182). To the best of our knowledge, this
is the largest described cohort of patients with these characteristics and this represents a major strength
of the study. Due to the retrospective nature of the study, we were not able to evaluate the difference
between the high-starting dose and low-starting dose mitotane regimen, which is certainly a limitation.
However, the fact that we included patients treated with both standard regimens reflects the reality in
the expert centers around the globe, because none of them has been proven to be superior. The high-dose
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starting regimen led to only a slightly but not significantly higher mitotane plasma levels within the
first 12 weeks of treatment [36] and in the clinical practice, mitotane dosage is adjusted according
to blood concentrations and patient tolerability after the first 2–4 weeks of therapy [9,13]. Another
important point of this study is that the genotyping of CYP2W1*6 and CYP2B6*6 SNPs is a cost-effective
analysis that may be done by the majority of labs and thus is easily applicable in the clinical practice.
Moreover, the genotyping of SNPs could be performed before starting mitotane, allowing clinicians
to pre-select those patients with advanced ACC who may not respond to mitotane and who may
for instance better benefit from more aggressive treatment (i.e., standard chemotherapy). This kind
of patients’ pre-selection is currently not possible with any other proposed predictive biomarkers
of response and could lead in the near future to an innovative personalized medicine approach in
the treatment of ACC patients. However, our findings should be further validated in a prospective
study. Moreover, functional in vitro experiments should be performed to better investigate the role of
CYP2W1*6 and CYP2B6*6 on mitotane metabolism.
4. Materials and Methods
4.1. Study Design and Population
We performed a multicenter retrospective study including ACC patients from 6 ENSAT centers
(www.ensat.org): two centers from Germany, three from Italy and one from Greece. We included
only Caucasian patients treated with mitotane monotherapy as first line medical treatment after
radical resection or in advanced disease. Other inclusion criteria were: availability of clinical and
histopathological data at diagnosis and during follow-up, and availability of whole blood sample for
genotyping. Exclusion criteria included previous or concomitant treatment with systemic cytotoxic
therapies, age at diagnosis less than 16 years old, incomplete follow-up and/or incomplete details
of mitotane treatment. Samples have been stored in the Interdisciplinary bank of biomaterial and
data Würzburg (IBDW) [37]. In total, we collected samples and data of 203 (F/M = 133/70) ACC
patients who had been treated with mitotane monotherapy between January 2002 and December 2017
(last follow-up). However, 21 patients did not fulfill all inclusion criteria and were excluded from
further analysis.
The study was approved by the local Ethics Committees of the University of Wuerzburg,
Germany (approval number 88/11) and was conducted in accordance with the principles of the
Declaration of Helsinki. Written informed consent was obtained from all patients.
4.2. Clinical Data, Mitotane Treatment and Endpoints Assessment
The evaluated clinical and histopathological characteristics of the patients at baseline included sex,
age at diagnosis, country of origin, tumor size initial tumor stage according to ENSAT classification [1],
hormonal secretion pattern, Weiss score, Ki67 proliferation index and R status. All patients received the
same mitotane formulation (Lysodren®, 500 mg tablets, from HRA Pharma, Paris, France), starting with
either a low-dose or a high-dose protocol according to standard clinical practice in each center [9,36].
Treatment was discontinued upon discretion of the local physician/investigator in case of unacceptable
toxicity, evidence of disease progression, or patients’ decision. During follow-up, all patients underwent
standardized follow-up every 3–6 months according to disease status [9]. These evaluations included
physical examination, biochemical workup and imaging procedures, including computed tomography
(CT) of chest and abdomen or fluorodeoxyglucose (FDG)-positron emission tomography (PET)/CT.
The baseline characteristics as well as data on mitotane treatment and follow-up were collected through
the ENSAT Registry (www.ens@t.org/registry).
We divided the patients in two groups according to tumor resection, ENSAT stage and disease
status: group A and group B. In group A we included patients who underwent radical resection of the
primary tumor and, in case of metastatic disease, together with complete metastasis resection and who
were treated adjuvantely with mitotane. In group B we included patients with not completely resectable,
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recurrent or advanced ACC who were treated with mitotane as first medical therapy. All endpoints
were evaluated separately for in group A and group B. The major endpoint was the correlation
between the presence of investigated SNPs and the achievement of the mitotane therapeutic levels,
defined by mitotane levels ≥14 mg/L for at least half of the treatment period. Mitotane levels were
routinely monitored in patients during the follow-up through the Lysosafe service (www.lysosafe.com).
Secondary endpoint included the response to mitotane treatment evaluated by TTP and DSS under
therapy. TTP was defined as the time from the start of mitotane until the first radiological evidence
of disease relapse or progression, or last follow-up or treatment discontinuation. DSS was defined
as the time from mitotane treatment start to disease-related death or last follow-up. In patients with
not completely resectable, recurrent or advanced disease we evaluated also the DCR, defined as the
proportion of patients whose best response was CR or PR or stable disease (SD) according to RECIST
1.1 criteria [28].
4.3. Genotyping and Sequencing of CYP2W1 and CYP2B6 Polymorphisms
We genotyped two CYP2W1 SNPs and two CYP2B6 SNPs, according to data available from
literature [17,23]. Specifically, we investigated for CYP2W1 (ENSG00000073067: ENST00000308919,
transcript position in coding sequence (CDS)): CYP2W1*2 (rs3735684, c.541G > A, p.A181T)
and CYP2W1*6 (rs3808348, c.1463C > T, p.P488L). The polymorphisms investigated for CYP2B6
(ENSG00000197408: ENST00000643956, position in CDS) were: CYP2B6*6 (rs3745274, c.516G > T,
p.Q172H) and CYP2B6 intronic variant (rs4803419, c.485-18C > T).
DNA was extracted from 2 mL of whole blood previously collected in ETDA tubes and stored
at −80 ◦C, using NucleoSpin® Blood L (#740954.20, Macherey-Nagel, Düren, Germany) following
the manufacturer’s instructions. The investigated polymorphisms were genotyped by Polymerase
Chain Reaction (PCR) using oligonucleotide primers of approximately 18–20 base pairs (Table S2).
30 ng of genomic DNA was used for PCR amplification, which was performed in a final volume of
25 µL containing 1.5 mM MgCl2, 0.2 µM of each primer, 200 µM dNTPs and 1 U Taq DNA Polymerase.
Cycling conditions were: 95 ◦C for 5 min followed by 35 cycles of denaturing at 94 ◦C (20 s), annealing at
58 or 60 ◦C (30 s) depending on primers, and elongation at 72 ◦C (1 min). Direct sequencing of PCR
products was performed according to Sanger [38] using the QuickStart Cycle Sequencing Kit (#608120,
AB Sciex, Beckman Coulter, Krefeld, Germany) on a CEQ8000 DNA Analyzer (AB Sciex).
4.4. Evaluation of Mitotane Related Adverse Events
Potential mitotane therapy related adverse events were regularly registered during the follow
up visits and assessed according the Common Terminology Criteria for Adverse Events (CTCAE)
version 4.03 [39]. According to the known spectrum of adverse effects of mitotane [8,9], we searched
the medical records for gastrointestinal (diarrhea, nausea, vomiting, flatulence, abdominal pain),
CNS-related (concentration impairment, confusion, amnesia, aphasia, depression, ataxia, dizziness,
vertigo, dysarthria, dysgraphia, dysgeusia), hepatic (increase of γ-glutamyl transferase, and aspartate
or alanine aminotransferase), endocrine (adrenal insufficiency, hypothyroidism, hypogonadism),
metabolic (increase of cholesterol levels), hematologic (leukopenia), dermatologic (rash, dry skin,
sweating), and musculoskeletal adverse events (myalgia, muscle cramps or pain), as well as
constitutional (asthenia, fatigue), ocular (visus alterations, blurred vision, conjunctivitis, retinal
vascular disorders), and other unspecific symptoms (dyspnea, fever, insomnia, restlessness infections,
sepsis). The occurrence of the different mitotane related adverse events, as well as the total numbers of
observed events, were then associated with all investigated SNPs.
4.5. Measurement of Mitotane Metabolites
For a subgroup of 29 patients we had available additional plasma sample collected during mitotane
treatment and stored at −80 ◦C for the measurement of o,p′-DDD and its two principal plasma
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metabolites, o,p′-DDE and o,p′-DDA. This analysis was carried out by a validated high-performance
liquid chromatography method coupled with ultraviolet detection (HPLC-UV), as previously described [40].
4.6. Statistical Analysis
The allele frequencies were compared to those found in the European population using the
1000 Genomes Project Phase 3 allele frequencies (ENSEMBLE, http://www.1000genomes.org/category/
frequently-asked-questions/population) and the HWE equilibrium was calculated within each country
of origin [26].
The Fisher’s exact test or the Chi-square test were used to investigate dichotomic variables,
while a two-sided t test (or non-parametric test) was used to test continuous variables as appropriate.
A non-parametric Kruskal-Wallis test, followed by Bonferroni post-hoc test, was used for comparison
among several groups for non-normal distributed variables. Correlations and 95% CI between
different parameters were evaluated by linear regression analysis. Association between dichotomic
and continuous variables were evaluated by Eta correlation. All survival curves were obtained by
Kaplan-Meier estimates and the differences between survival curves were assessed by the Log Rank
(Mantel-Cox) test. Univariate analysis followed by multivariate regression analysis were performed by
Cox proportional hazard regression model to identify those factors that might independently influence
survival. In survival and regression analyses we considered all the investigated SNPs as well as
clinical-pathological parameters that have been describe to have a prognostic role in ACC patients,
including the achievement of mitotane therapeutic range (as previously defined) [12], Ki67 index
(cut-off ≥ 20%) [4,41], hormonal secretion (cortisol secreting alone or in combination with other steroids
vs other steroids-secreting or inactive) [42], and age (cut-off ≥ 50 years) [5,6]. The ENSAT tumor
stage (I-II vs III-IV in patients after radical resection of primary tumor and, in one case, after radical
resection of primary tumor and associated single liver metastasis) [1] was evaluated in the group
treated adiuvantly with mitotane. In patients with not completely resectable, recurrent or advanced
disease, we considered preM-TTP, evaluated as the time from ACC diagnosis to first radiological
evidence recurrence or metastasis. According to preM-TTP, patients were divided in three categories:
preM-TTP ≤ 3 months, between 3 and 24 months, and ≥24 months. The tumor resection status
(complete resection (R0) or not assessed (RX) vs microscopic (R1) or macroscopic (R2) incomplete
resection) [2] was evaluated only in the group of patients with advanced disease, since, by definition,
in the group of patients who had radical resection did not include patients with R1 or R2 resection.
To evaluate the predictor factors of mitotane plasma concentration we performed a multivariate
logistic regression analysis and OR were calculated with 95% CI. Statistical analyses were made using
GraphPad Prism (version 5.0, La Jolla, CA, USA) and SPSS Software (PASW Version 21.0, SPSS Inc.,
Chicago, IL, USA). p values < 0.05 were considered as statistically significant.
5. Conclusions
We suggest that the association of CYP2W1*6 and CYP2B6*6 may be used to predict the individual
response to mitotane treatment. Our study provides the basis for a clinical trial to test the value of
genotyping for CYP2W1*6 and CYP2B6*6 SNPs in ACC patients treated with mitotane monotherapy.
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